Can smarter screening cut prostate cancer deaths?
NCT ID NCT07155759
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 7,500 men aged 50-74 to see which prostate cancer screening method works best over time. Some men were invited for a standard PSA test, while others had a newer approach using PSA plus a biomarker test and MRI. Researchers will track prostate cancer deaths, diagnoses, and healthcare use through registries to find out if the advanced screening saves more lives.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that combining PSA with biomarkers and MRI is a better way to screen for prostate cancer, potentially reducing unnecessary biopsies and deaths.
- What could go wrong
- This is an observational follow-up study, not a new treatment. Results depend on registry data, which may have limitations, and the screening approach may not reduce mortality as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Karolinska Institutet
Stockholm, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?